Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant
NCT05031897
Suspended
This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therapy for many hematopoietic malignancies, however this regimen results in higher rates of TRM than other forms of treatment. In recent years, less intense conditioning regimens with radiation and chemotherapy prior to HSCT have been developed. Radiation... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia, Chronic Lymphocytic Leukemia, Chronic Myelomonocytic Leukemia, Essential Thrombocythemia, Hodgkin Lymphoma, Myelofibrosis, Myeloid Neoplasm, Non-Hodgkin Lymphoma, Polycythemia Vera, Small Lymphocytic Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphatic System Neoplasm, Multiple Myeloma, Myelodysplastic Syndrome
Register for Updates
'ADVANCE' (A Pilot Trial)
NCT03858322
Active Not Recruiting
This study is being conducted to carefully study how chemotherapy is tolerated in group of patients age 70.
Gender:
ALL
Ages:
70 years and above
Trial Updated:
08/05/2025
Locations: City of Hope National Medical Center, Duarte, California +4 locations
Conditions: Breast Cancer
Register for Updates
Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
NCT02876302
Active Not Recruiting
This research study is studying Ruxolitinib as possible treatment for Inflammatory Breast Cancer (IBC). The Following drugs will be use in combination with Ruxolinitinib. * Paclitaxel (also called Taxol) * Doxorubicin also called Adriamycin * Cyclophosphamide, also called Cytoxan
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +3 locations
Conditions: Inflammatory Breast Cancer (IBC)
Register for Updates
Rapid Administration Pilot for Infusing Dinutuximab
NCT05421897
Recruiting
Studies have shown that the anti-GD2 human-mouse chimeric monoclonal antibody dinutuximab has contributed significantly to the improvement of treatment for children with high-risk neuroblastoma and has become a mainstay in treating high risk neuroblastoma in children as part of up-front therapy and relapsed/refractory therapy. The administration of dinutuximab requires a significant amount of time and resources to complete the 10-20 hour standard infusion time for 4 days in the inpatient setting... Read More
Gender:
ALL
Ages:
1 year and above
Trial Updated:
08/04/2025
Locations: Childrens Hospital Los Angeles, Los Angeles, California
Conditions: Neuroblastoma
Register for Updates
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
NCT07115745
Not Yet Recruiting
The purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-targeted CART cell product, in participants with severe, refractory autoimmune diseases.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Local Institution - 0036, New York, New York +31 locations
Conditions: Refractory Autoimmune Diseases
Register for Updates
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
NCT06191744
Recruiting
Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with previously untreated FL. Adverse events and change in disease condition will be assessed. Epcoritamab is an investigat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Scripps Mercy Hospital /ID# 265393, San Diego, California +244 locations
Conditions: Follicular Lymphoma (FL)
Register for Updates
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
NCT05283720
Recruiting
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and tolerability of epcoritamab in combination with anti-neoplastic agents in adult participants with Non-Hodgkin lymphoma (NHL). Adverse events and change in disease activity will be assessed. Epcoritamab is an investigational drug being developed for the treatment of NHL. Study doctors put the participants in grou... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: The University of Arizona Cancer Center - North Campus /ID# 242219, Tucson, Arizona +73 locations
Conditions: Non-Hodgkin Lymphoma
Register for Updates
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
NCT01659151
Active Not Recruiting
The purpose of this study is to find out more about the effects of an investigational combination of medicines, which includes special immune cells (T-cells). A T-cell is a type of lymphocyte, or white blood cell. Lymphocytes are a kind of white blood cell that protect the body from viral infections, help other cells fight bacterial and fungal infections, produce antibodies, fight cancers, and coordinate the activities of other cells in the immune system.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Metastatic Melanoma
Register for Updates
MOv19-BBz CAR T Cells in FRa+ Cancers
NCT07116057
Not Yet Recruiting
This is a Phase I open-label clinical trial to assess the safety, feasibility, and preliminary efficacy of intrapleural administration of MOv19-BBz CAR T cells in patients with FRa+ cancers. This study will be initiated in patients with metastatic or recurrent non-small cell lung cancer (NSCLC) only. Subjects will receive a single dose of MOv19-BBz CAR T cells via intrapleural infusion following lymphodepleting chemotherapy. Subjects without an existing intra-pleural catheter will have a tempora... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Metastatic Non Small Cell Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma
Register for Updates
Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)
NCT03396575
Terminated
The standard of care for children with DIPG includes focal radiotherapy (RT) but outcomes have remained dismal despite this treatment. The addition of oral Temozolomide (TMZ) concurrently with RT followed by monthly TMZ was also found to be safe but ineffective. Recent studies in adults have shown that certain types of chemotherapy induce a profound but transient lymphopenia (low blood lymphocytes) and vaccinating and/or the adoptive transfer of tumor-specific lymphocytes into the cancer patient... Read More
Gender:
ALL
Ages:
Between 3 years and 30 years
Trial Updated:
08/04/2025
Locations: UF Health Shands Children's Hospital, Gainesville, Florida
Conditions: Diffuse Intrinsic Pontine Glioma (DIPG), Brain Stem Glioma
Register for Updates
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
NCT04663347
Active Not Recruiting
The purpose of this trial is to measure the safety and effectiveness of epcoritamab (EPKINLY™), either by itself or together with other therapies, when treating participants with B-cell non-Hodgkin Lymphoma (B-NHL). The aim of the first part of the trial is to identify the most appropriate dose of epcoritamab, and the aim of the second part of the trial is to assess the selected epcoritamab dose in a larger group of participants with B-NHL. All participants in this trial will receive either epco... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +57 locations
Conditions: Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Register for Updates
Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
NCT06799195
Recruiting
This study will compare post-transplant health-related quality of life following the use of standard versus attenuated dose of post-transplant cyclophosphamide in addition to two-drug graft-versus-host disease (GVHD) prophylaxis among recipients of allogeneic hematopoietic stem cell transplant.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
08/04/2025
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Hematological Malignancies, Graft-versus-Host Disease (GVHD)
Register for Updates